HIV drug repurposed in fight against Tough-to-Treat vulvar cancer
NCT ID NCT04169763
Summary
This early-stage study is testing whether adding an HIV drug called nelfinavir to standard chemotherapy (cisplatin) and radiation can better control advanced vulvar cancer that cannot be removed by surgery. The main goal is to find the safest and most effective dose of nelfinavir for this combination. The study will enroll about 25 patients to carefully monitor side effects and see if the three-part treatment helps control the cancer and improve survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II VULVAR CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.